A 28-year-old military veteran, a married father of two, presents to his primary care physician, reporting problems with insomnia and nightmares.

Should this patient be assessed for post-traumatic stress disorder?

Given the patient’s military background and the symptoms of insomnia and nightmares, which are consistent with posttraumatic stress disorder (PTSD), this diagnosis should be considered.

Further inquiry indicates that this patient returned from deployment in Afghanistan two years earlier. Previous exposure to potentially traumatic events in the military (e.g., combat, witnessing injury or death of comrades, witnessing atrocity) should prompt screening for the presence of this disorder.1–3 Among civilians, exposure to events that may have resulted in fear of death or bodily injury, or witnessing death or bodily injury, also indicate a need to screen for psychological distress or trauma.1–3 Many patients will not spontaneously offer this information. The Primary Care PTSD screen (Box 1) is a brief, validated instrument (sensitivity 0.78, specificity 0.87) for use in primary care settings, including with combat veterans.1

There is no clear evidence of an elevated risk of mental health problems related to military deployment per se. However, there is evidence of a strong link between exposure to combat and/or the witnessing of atrocities and the development of mental health disorders, including PTSD. A dose–response relationship has been shown, with greater exposure to combat or atrocity more likely to lead to PTSD.2

Does this patient have PTSD?

Exposure to a traumatic event is required for a diagnosis of PTSD, but not all exposure to potentially traumatic events leads to development of the disorder. According to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V), the diagnosis of PTSD requires the presence of symptoms, for more than one month, in each of four categories: intrusion symptoms (e.g., intrusive, distressing memories or nightmares of the traumatic event or events), avoidance (e.g., persistent effortful avoidance of thoughts, feelings, people or places that act as reminders of the traumatic events), negative alterations in cognition and mood (e.g., persistent and/or distorted negative expectations about oneself, others or the world) and alterations in arousal and reactivity (e.g., irritable or aggressive behaviour, sleep disturbance). In PTSD, these symptoms result in clinically significant distress or impairment of functioning. Symptoms lasting for less than one month are suggestive of an acute stress disorder (also as outlined in DSM-V).

Comorbidity, which can worsen the prognosis, occurs in 79%–88% of individuals with PTSD.4 As such, this patient should also be screened for depression, anxiety and substance abuse.3,4

Is this patient at increased risk of suicide?

A recent review of the relation between PTSD and suicide risk did not show an elevated risk of suicide completion by those with PTSD. However, an association was found between PTSD and prior suicide attempts, as well as current suicidal ideation; the risk was greater in the pres-

Box 1: Screening for posttraumatic stress disorder: the Primary Care PTSD Screen1

In your life, have you ever had any experience that was so frightening, horrible or upsetting that, in the past month,

- you have had nightmares about it or thought about it when you did not want to? Yes/No
- you tried hard not to think about it or went out of your way to avoid situations that reminded you of it? Yes/No
- you were constantly on guard, watchful or easily startled? Yes/No
- you felt numb or detached from others, activities or your surroundings? Yes/No

The screening result should be considered “positive” if a patient answers “yes” to any three items.
ence of concurrent depression. This patient should be asked about current suicidal thoughts or plans and should also be questioned about access to weapons or other lethal means.

**What are some initial interventions that can be used?**

Box 2 offers a general approach to first-line treatment of PTSD in primary care. Psychological interventions specifically developed for PTSD have the strongest evidence for efficacy, particularly trauma-focused cognitive behavioural therapies that address maladaptive thinking (e.g., responsibility, guilt related to the traumatic incident) and exposure therapies that involve imaginal reliving of aspects of the traumatic events. These interventions are significantly more effective than supportive treatment and nonspecific therapies. Notably, for nonsymptomatic individuals, the use of psychological intervention after exposure to trauma is potentially harmful.

The first-line pharmacologic treatment for PTSD is selective serotonin reuptake inhibitors. Because partial response to treatment is common, approaches that combine psychotherapy and pharmacotherapy are frequently used. Pharmacologic therapy may be considered as the initial intervention if the patient’s condition is not sufficiently stable to allow him or her to engage in trauma-focused therapy, if the patient is unwilling to engage in therapy or if there is a high level of dissociative symptoms. There is modest evidence for augmentation of therapy with an atypical antipsychotic (i.e., risperidone or olanzapine) in patients with no response to monotherapy with selective serotonin reuptake inhibitors or serotonin–norepinephrine reuptake inhibitors. However, the potential adverse effect of atypical antipsychotic agents on the patient’s metabolic profile should be taken into consideration. There is no evidence to support the use of benzodiazepines, which may cause harm.

**When should referral be considered?**

Primary care physicians may decide to involve intraprofessional team members, particularly if they do not have expertise in treating psychological trauma, in working with military personnel or in delivering evidence-based, trauma-focused psychotherapy. Referral to a psychiatrist should be considered if acute safety concerns are identified or if the patient’s PTSD symptoms are refractory to the treatments outlined above. Specialized care is often available for military personnel and their families (Box 3).

**What is the long-term prognosis for this patient?**

Trauma-focused therapy has been shown to significantly reduce symptoms of PTSD, to de-
crease symptom severity and to lessen symptoms of depression and anxiety. To date, no adequate trials have compared responses to trauma-focused psychotherapy and pharmacologic treatment. However, among people with a partial response to pharmacologic agents, further improvement has been documented with psychotherapy. Typically, military personnel experience a more chronic course of PTSD and their response to interventions is less robust than people with PTSD from nonmilitary causes; however, current evidence suggests that this may not be true for veterans of more recent wars, such as this patient.

The case revisited
Initial psychoeducation allowed the patient to understand his nightmares and sleep difficulties within the context of PTSD. He and his family sought resources and support through a military support program. His primary care physician referred him for trauma-focused cognitive behavioural therapy, which resulted in partial reduction in his symptoms. After 10 weeks of treatment, he was also started on paroxetine, in combination with the cognitive behavioural therapy. He responded well to the medication after six weeks and will continue taking it for one year.

References

Affiliations: Northern Psychiatric Outreach Program and Telepsychiatry, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, Ont.